The numerous observations that both CD44 and STAT3 are critically involved in the VEGF pathway and tumor angiogenesis indicate that dual targeting of both factors could be a promising therapeutic target to improve antiangiogenic treatment in ovarian cancer. The gene discussed is VEGFA; the disease is neoplasm.